Relonchem Ltd Cheshire House, Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: Relonchem Ltd Cheshire House, Pharmaceutical Import Records from India — 3 Products, $5.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Relonchem Ltd Cheshire House, — Pharmaceutical Importer Profile (2026) | 3 Products, $5.6M Trade | TransData Nexus

Relonchem Ltd Cheshire House,

Pharmaceutical Importer · United Kingdom · Antihistamines & Allergy Focus · $5.6M Total Trade · DGFT Verified

Relonchem Ltd Cheshire House, is a pharmaceutical importer based in United Kingdom with a total trade value of $5.6M across 3 products in 2 therapeutic categories. Based on 206 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Relonchem Ltd Cheshire House, sources from 1 verified Indian supplier, with Marksans Pharma Limited accounting for 100.0% of imports.

Relonchem Ltd Cheshire House, — Import Portfolio & Supplier Network

Relonchem Ltd Cheshire House, import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Relonchem Ltd Cheshire House,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Marksans Pharma Limited	$12.5M	575	100.0%

Relonchem Ltd Cheshire House, sources from 1 verified Indian supplier across 416 distinct formulations. The sourcing is highly concentrated — Marksans Pharma Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Pharmaceutical products - gliclazide 80MG tablets batch no: 140353	$111.7K	3
Pharmaceutical products - cetirizine hydrochloride 10 MG tablets batch no	$89.5K	2
Pharmaceutical products - paracetamol 500 MG capsules batch no: 240256	$77.3K	2
Pharmaceutical products - loratadine 10MG tablets batch no	$77.2K	2
Pharmaceutical products - cetirizine hydrochloride 10 MG tablets batch no: 140532	$76.7K	3
Pharmaceutical products -cetirizine hydrochloride 10 MG tablets batch no	$75.5K	3
Pharmaceutical products - loratadine 10MG tablets batch no	$74.5K	2
Pharmaceutical products - paracetamol 500 MG capsules batch no: 250137	$73.2K	2
Pharmaceutical products - cetirizine hydrochloride 10 MG tablets batch no	$71.2K	2
Pharmaceutical products - cetirizine hydrochloride 10 MG tablets batch no	$71.0K	3
Pharmaceutical products - loratadine 10MG tablets batch no	$65.6K	3
Pharmaceutical products - loratadine 10MG tablets batch no	$65.1K	3
Pharmaceutical products - loratadine 10MG tablets batch no	$63.4K	3
Pharmaceutical products - paracetamol 500 MG capsules batch no: 240204,240205	$59.9K	3
Pharmaceutical products - propranolol 10MG tablets BP batch no	$59.6K	2

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Loratadine	Antihistamines & Allergy	$2.6M	101	1.5%	5
2	Cetirizine	Antihistamines & Allergy	$2.4M	83	1.3%	14
3	Propranolol	Cardiovascular	$559.5K	22	1.0%	6

Relonchem Ltd Cheshire House, imports 3 pharmaceutical products across 2 categories into United Kingdom totaling $5.6M.

Relonchem Ltd Cheshire House, — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Relonchem Ltd, established in 2002, is an independent generic pharmaceutical company headquartered at Cheshire House, Gorsey Lane, Widnes, Cheshire, England, WA8 0RP. The company specializes in the wholesale distribution of pharmaceutical goods, offering a diverse range of own-label healthcare products across various therapeutic areas. These include anti-diabetic, anti-hypertensive, anti-depressant, anti-cancer, anti-ulcerative, anti-viral, allergy relief, and pain relief medications.

In 2008, Relonchem Ltd was acquired by Marksans Pharma Ltd, a prominent pharmaceutical manufacturer based in Mumbai, India, with operations in the UK, Germany, USA, Canada, and Australia. This acquisition has enabled Relonchem to expand its product portfolio and enhance its manufacturing capabilities.

2Distribution Network

Relonchem Ltd operates from its headquarters in Widnes, Cheshire, serving the United Kingdom market. The company maintains a state-of-the-art, MHRA-approved manufacturing facility, which has undergone significant investments to produce a variety of tablets, capsules, and sachets. This facility ensures compliance with Good Manufacturing Practice (GMP) standards, guaranteeing the quality and efficacy of its products.

3Industry Role

As a pharmaceutical wholesaler, Relonchem Ltd plays a crucial role in the UK's pharmaceutical supply chain. The company imports a range of finished pharmaceutical formulations from India, including antihistamines and cardiovascular medications, to meet the diverse needs of the UK market. Its strategic focus on generic pharmaceuticals allows it to offer cost-effective alternatives to branded medications, thereby enhancing accessibility for patients.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Relonchem Ltd Cheshire House,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Relonchem Ltd's sourcing strategy is highly concentrated, with a significant portion of its pharmaceutical imports originating from a single supplier, Marksans Pharma Ltd. This single-source dependency could pose risks related to supply chain disruptions, such as production delays or regulatory challenges affecting the supplier. However, the long-standing relationship between Relonchem and Marksans Pharma suggests a stable and reliable partnership, potentially mitigating some of these risks.

2Supply Chain Resilience

The resilience of Relonchem Ltd's supply chain is closely tied to its reliance on Marksans Pharma Ltd. While this partnership offers consistency in product quality and supply, it also exposes Relonchem to potential vulnerabilities if Marksans Pharma faces operational challenges. The company's focus on importing a diverse range of formulations, including antihistamines and cardiovascular medications, indicates an effort to mitigate risks by not overly depending on a single product line.

3Strategic Implications

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) is the primary regulatory body overseeing pharmaceutical imports. Key legislation governing pharmaceutical imports includes the Human Medicines Regulations 2012, which implement European Union directives into UK law. The marketing authorization pathway for Indian generics involves obtaining a UK marketing authorization, either through the centralized procedure or by mutual recognition, ensuring compliance with UK-specific requirements.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the UK mandate that all imported medicines must have a valid marketing authorization issued by the MHRA. Manufacturers and suppliers must adhere to Good Manufacturing Practice (GMP) standards recognized by the MHRA, which may include EU GMP, WHO GMP, or PIC/S certifications. Additionally, wholesale distribution authorization is required for entities involved in the distribution of medicinal products within the UK.

3Quality & Labeling

Relonchem Ltd Cheshire House, — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Relonchem Ltd's focus on importing antihistamines and cardiovascular medications aligns with prevalent health concerns in the UK, such as allergies and cardiovascular diseases. The market demand for these products is driven by the high incidence of allergic reactions and heart-related conditions among the UK population. By sourcing these products from India, Relonchem can offer cost-effective alternatives to branded medications, enhancing accessibility for patients.

2Sourcing Profile

Relonchem Ltd's sourcing strategy emphasizes generic drug procurement, particularly in the therapeutic areas of antihistamines and cardiovascular medications. India's robust pharmaceutical manufacturing sector, with its adherence to international quality standards, makes it a preferred sourcing destination. This approach allows Relonchem to provide a diverse range of formulations to meet the varied needs of the UK market.

3Market Positioning

Based on its product mix, Relonchem Ltd serves the wholesale distribution segment of the UK pharmaceutical market. By importing generic formulations, the company caters to retail pharmacies, hospitals, and other healthcare providers seeking cost-effective alternatives to branded medications. This positioning enables Relonchem to contribute to the overall efficiency and affordability of the UK's healthcare system.

Seller's Guide — How to Become a Supplier to Relonchem Ltd Cheshire House,

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Relonchem Ltd, especially if they can meet the stringent quality and regulatory standards required by the UK market. Gaps in Relonchem's current sourcing may include specific formulations or dosage forms not currently offered. By identifying and addressing these gaps, Indian exporters can position themselves as valuable partners to Relonchem, expanding their market reach in the UK.

2Requirements & Qualifications

Indian exporters aiming to supply Relonchem Ltd and the UK market must obtain a valid UK marketing authorization for their products. They must adhere to GMP standards recognized by the MHRA, such as EU GMP, WHO GMP, or PIC/S certifications. Additionally, compliance with UK labeling requirements, including English language labeling and serialization mandates, is essential. Ensuring these qualifications will facilitate successful market entry and distribution within the UK.

3How to Approach

Frequently Asked Questions — Relonchem Ltd Cheshire House,

What products does Relonchem Ltd Cheshire House, import from India?

Relonchem Ltd Cheshire House, imports 3 pharmaceutical products across 2 categories. Top imports: Loratadine ($2.6M), Cetirizine ($2.4M), Propranolol ($559.5K).

Who supplies pharmaceuticals to Relonchem Ltd Cheshire House, from India?

Relonchem Ltd Cheshire House, sources from 1 verified Indian suppliers. The primary supplier is Marksans Pharma Limited (100.0% of imports, $12.5M).

What is Relonchem Ltd Cheshire House,'s total pharmaceutical import value?

Relonchem Ltd Cheshire House,'s total pharmaceutical import value from India is $5.6M, based on 206 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Relonchem Ltd Cheshire House, focus on?

Relonchem Ltd Cheshire House, imports across 2 categories. The largest: Antihistamines & Allergy (90.0%), Cardiovascular (10.0%).

Get Full Relonchem Ltd Cheshire House, Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.